2019
Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation
Egli-Spichtig D, Imenez Silva P, Glaudemans B, Gehring N, Bettoni C, Zhang M, Pastor-Arroyo E, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler G, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger R, Frew I, Wagner C. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney International 2019, 96: 890-905. PMID: 31301888, DOI: 10.1016/j.kint.2019.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsCell LineCohort StudiesDisease Models, AnimalFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansInflammatory Bowel DiseasesInterleukin-10KidneyMaleMiceMice, TransgenicMiddle AgedNuclear Receptor Subfamily 4, Group A, Member 2Primary Cell CultureRenal Insufficiency, ChronicTumor Necrosis Factor-alphaConceptsChronic kidney diseaseTumor necrosis factorPlasma FGF23Kidney diseaseFGF23 expressionFGF23 levelsNecrosis factorGrowth factor 23 levelsFibroblast growth factor 23Inflammatory cytokines tumor necrosis factorCytokines tumor necrosis factorInflammatory bowel diseaseGrowth factor 23Normal kidney functionIL10-deficient micePopulation-based cohortAntibody-mediated neutralizationOrphan nuclear receptor Nurr1Nuclear receptor Nurr1Cause mortalityRenal inflammationTNF neutralizationBowel diseaseFactor 23Kidney function
2013
Dabigatran and Kidney Disease: A Bad Combination
Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and Kidney Disease: A Bad Combination. Clinical Journal Of The American Society Of Nephrology 2013, 8: 1591-1597. PMID: 23868901, PMCID: PMC3805067, DOI: 10.2215/cjn.01260213.Peer-Reviewed Original ResearchConceptsAnticoagulant effectPharmacokinetic profileOral direct thrombin inhibitorContinuous renal replacement therapyRoutine laboratory monitoringSerious bleeding eventsHigh bleeding riskReduced kidney functionRenal replacement therapyDirect thrombin inhibitorDrug Administration approvalLaboratory monitoring testsBleeding eventsBleeding riskSerious bleedingThromboembolic complicationsDose adjustmentHemodialysis cathetersKidney functionKidney diseaseReplacement therapyLaboratory monitoringAdministration approvalClinical indicationsDrug levels